Previous 10 | Next 10 |
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
2024-03-18 17:35:27 ET More on etc. A Bitcoin Strategy Using The 200-Day Simple Moving Average (Technical Analysis) Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Re-Emerging Markets Biggest stock movers today: NVDA, GOOG, FOUR and more ...
2024-03-18 17:35:14 ET More on Harrow Health Harrow's Drug Iheezo Is Off To A Great Start Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity Harrow says dry eye drug Vevye n...
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024 Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tue...
2024-03-02 14:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-21 11:40:00 ET Summary SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. SRK Fund I, LP appreciated 17.15% during 2023. I believe our holdings present a significant opportunity with minimal fundamental downside and s...
2024-02-19 09:30:00 ET Summary Harrow Inc. is leveraging its existing customer base in the compounded ophthalmic pharmaceutical products business to expand into branded pharmaceuticals. The company's first major branded drug, Iheezo, initially faced skepticism but has seen signifi...
2024-02-05 03:26:15 ET Summary Harrow has two outstanding notes on offer that come up for maturity in 2026 and 2027. The 11.875% Senior Notes due 2027 offer a compelling 11.5% yield on cost and trade at a just under 3% premium to their $25 per share liquidation value. Cash and...
2024-01-30 16:03:51 ET Summary Harrow, Inc.'s stock price has fallen due to disappointing earnings releases in Q1, Q2, and Q3 of 2023. The company's various revenue buckets have not performed as well as expected, leading to a decline in revenue. Despite short-term challenges, ...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company’s Board of Directors, effective immediately. Harrow’s Board now consists of six members. “I am deligh...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 10:00:07 ET Chase Knickerbocker from Craig-Hallum issued a price target of $30.00 for HROW on 2024-06-21 08:28:00. The adjusted price target was set to $30.00. At the time of the announcement, HROW was trading at $19.93. The overall price target consensus is a...
Harrow Health, Inc. (NASDAQ: HROW) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 13.77% on the day to $20.08. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an op...